Delayed-Release Budesonide in a Patient With Progressive IgA Nephropathy and Stage 4 Chronic Kidney Disease: A Case Report

• Główni autorzy: Zohreh Gholizadeh Ghozloujeh MD (Autor), Vinay Srinivasan MD, MBA (Autor), Ayman Al Jurdi MD (Autor), Amir Abdipour MD (Autor), Sayna Norouzi MD (Autor)
• Format: Książka
• Wydane: SAGE Publishing, 2024-06-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Delayed-release (DR) budesonide received expedited approval from the US Food and Drug Administration (FDA) as a treatment for reducing proteinuria in individuals with primary IgA nephropathy (IgAN) who are at significant risk of disease progression. The approval was based on clinical trials primaril...